Kroger cuts full-year sales outlook as pharmacy headwinds and a Cyclospora outbreak pressure results, despite strong e-commerce gains and private label growth.
Kroger reported mixed Q2 2026 results with lowered full-year guidance and pharmacy headwinds, but cost savings and e-commerce growth provide support.
Kroger reported mixed Q2 2026 results, lowering its full-year identical sales guidance to a range of 0.2% to 0.8%. The retailer faces significant pharmacy headwinds from the Inflation Reduction Act and a Cyclospora outbreak, though aggressive cost-saving measures and 20% e-commerce growth helped stabilize the company's operating model.
The guidance reduction reflects first-half performance and anticipated headwinds from the Inflation Reduction Act affecting pharmacy sales, alongside impacts from a Cyclospora outbreak and egg deflation.